What do systematic reviews say?

Intervention not reported

• Standard versus biofilm antimicrobial susceptibility testing to guide antibiotic therapy in cystic fibrosis 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 38 participants
  Moderate

Salicylic acid vs tretinoin

• Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha‐hydroxy acid) for acne 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 46 participants
  Very low

Summary of findings: amikacin liposome inhalation suspension (ALIS) vs tobramycin

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 294 participants
  Moderate

Single‐dose intravesical chemotherapy instillation vs placebo or observation after nephroureterectomy

The review found no eligible studies for this question.

• Single‐dose intravesical chemotherapy after nephroureterectomy for upper tract urothelial carcinoma 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Impact of extended vs standard lymph node dissection on overall survival among patients with urothelial cancer of the bladder

The review found no eligible studies for this question.

• Extended versus standard lymph node dissection for urothelial carcinoma of the bladder in patients undergoing radical… 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: colistimethate dry powder for inhalation (Colobreathe®) vs tobramycin

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 374 participants
  Low

Summary of findings: continuous cycles alternating aztreonam lysine for inhalation with tobramycin for inhalation solution vs continuous cycles alternating placebo with tobramycin

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 90 participants
  Low

Intervention not reported

The review found no eligible studies for this question.

• Fenofibrate for diabetic retinopathy 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intervention not reported

• Oral paracetamol (acetaminophen) for cancer pain 2017 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 93 participants
  Very low

Intervention not reported

• Aminoadamantanes for chronic hepatitis C 2014 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 1181 participants
  Very low

Sulphasalazine vs placebo

The review found no eligible studies for this question.

• Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Summary of findings: aztreonam lysine for inhalation vs tobramycin

• Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 268 participants
  Moderate

Pembrolizumab vs chemotherapy alone

Pembrolizumab may leads to higher quality of life (Change from baseline to week 15) compared with chemotherapy (low certainty).

• Pembrolizumab monotherapy versus chemotherapy for treatment of advanced urothelial carcinoma with disease progression… 2018 · Cochrane Headline outcomes only
  MD 9.05 [4.61, 13.5]
  1 study · 519 participants
  Low

Summary of findings table ‐ Cannabis vs placebo

• Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis 2022 · Cochrane Headline outcomes only
  no estimate extracted
  8 studies · 1942 participants
  Low

Targeted immunotherapy alone vs standard targeted therapies

Targeted immunotherapy alone probably leads to higher quality of life: Clinically relevant improvement in FKSI‐DRS compared with standard targeted therapies (moderate certainty).

• Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
  RR 1.51 [1.28, 1.78]
  1 study · 704 participants
  Moderate
• Immunotherapy for metastatic renal cell carcinoma 2017 · Cochrane Headline outcomes only
  RR 1.37
  1 study · 703 participants
  Moderate

Intervention not reported

• Gamma aminobutyric acid (GABA) modulators for amyotrophic lateral sclerosis/motor neuron disease 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 128 participants
  Moderate

Intervention not reported

The intervention showed no clear difference in health‐related quality of life scores, measured by SF‐36 (range 0 to… (low certainty).

• Surgical versus medical interventions for chronic rhinosinusitis with nasal polyps 2014 · Cochrane Headline outcomes only
  MD 0.6
  1 study · 95 participants
  Low

Intervention not reported

The review found no eligible studies for this question.

• Gamma‐aminobutyric acid agonists for antipsychotic‐induced tardive dyskinesia 2018 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found